ePrints

Extra-mandibular Osteoradionecrosis after the Treatment of Head and Neck Cancer

Lookup NU author(s): Dr Charles Kelly, Michael Jackson, Nick West, Dr Naomi Willis

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2023. Aims: Osteoradionecrosis (ORN) is a serious toxicity of head and neck radiotherapy. It predominantly affects the mandible. Extra-mandibular ORN is rare. The aim of this study was to report the incidence and outcomes of extra-mandibular ORNs from a large institutional database. Materials and methods: In total, 2303 head and neck cancer patients were treated with radical or adjuvant radiotherapy. Of these, extra-mandibular ORN developed in 13 patients (0.5%). Results: Maxillary ORNs (n = 8) were a consequence of the treatment of various primaries (oropharynx = 3, sinonasal = 2, maxilla = 2, parotid = 1). The median interval from the end of radiotherapy to the development of ORN was 7.5 months (range 3–42 months). The median radiotherapy dose in the centre of the ORN was 48.5 Gy (range 22–66.5 Gy). Four patients (50%) healed in 7, 14, 20 and 41 months. All temporal bone ORNs (n = 5) developed after treatment to the parotid gland (of a total of 115 patients who received radiotherapy for parotid gland malignancy). The median interval from the end of radiotherapy to the development of ORN was 41 months (range 20–68 months). The median total dose in the centre of the ORN was 63.5 Gy (range 60.2–65.3 Gy). ORN healed in only one patient after 32 months of treatment with repeated debridement and topical betamethasone cream. Conclusion: Extra-mandibular ORN is a rare late toxicity and this current study provides useful information on its incidence and outcome. The risk of temporal bone ORN should be considered in the treatment of parotid malignancies and patients should be counselled. More research is required to determine the optimal management of extra-mandibular ORN, particularly on the role of the PENTOCLO regimen.

Publication metadata

Author(s): Kovarik PDE, Patil R, Cvek J, Kelly C, Jackson M, Mackenzie L, West N, Willis N, Kovarik JP, Banks R, Kennedy M, Adams J, Iqbal MS

Publication type: Article

Publication status: Published

Journal: Clinical Oncology

Year: 2023

Volume: 35

Issue: 9

Pages: e498-e505

Print publication date: 01/09/2023

Online publication date: 27/06/2023

Acceptance date: 02/04/2018

ISSN (print): 0936-6555

ISSN (electronic): 1433-2981

Publisher: Elsevier Ltd

URL: https://doi.org/10.1016/j.clon.2023.06.013

DOI: 10.1016/j.clon.2023.06.013

PubMed id: 37433701

Altmetrics

Share